COVID-19 Funding Opportunities

The MSI STEM Research & Development Consortium (MSRDC) - Additional funding for COVID-19-related research

The MSI STEM Research & Development Consortium (MSRDC)

The Icahn School of Medicine at Mount Sinai has become a partner institution of the MSI STEM Research & Development Consortium (MSRDC). This partnership offers significant advantages to Mount Sinai researchers and the consortium members through collaborative work. It also offers funding opportunities that would otherwise be unavailable to Mount Sinai researchers.  MSRDC awards are “other transactions” rather than traditional grants or contracts. These non-competed awards bypass solicitation, allowing for a direct connection between collaborative partners and government program managers. This unusual funding mechanism connect collaborative partners with Minority-Serving Institutions (MSI), such as Historically Black Colleges and Universities (HBCUs), to work on government projects.

Some Advantages – Skip The Line:

  • Access a community of researchers and partners
  • Leverage unique funding vehicles to secure direct, non-competed awards
  • Work together to produce a Scope of Work (SOW) and a Request for Proposal (RFP)
  • Move your idea from concept to award in as few as 90 days, (or fewer)

Some of the federal agencies involved include:

  • Centers for Disease Control and Prevention (CDC)
  • National Institutes of Health (NIH)
  • Food and Drug Administration (FDA)
  • Department of State (DOS)
  • Department of Defense (DoD)
  • Department of Education (DoE)
  • Homeland Security
  • Communications-Electronics Research Development Center (CERDEC)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Army Material Systems Analysts Activity (AMSAA)
  • Department of Transportation

MSRDC Innovation Prospectus
MSRDC  Presentation

Submit your capabilities to get started.  For additional information or assistance, email Anthony Smalls.

Anthony Smalls, MBA
Program Manager
Research Operations & Infrastructure
Icahn School of Medicine at Mount Sinai
New York, NY 10029
Phone:  (212) 241- 0640

If you have any questions for MSRDC, please contact them below:
info@msrdconsortium.org (All other inquiries)
busdev@msrdconsortium.org (For questions about working with our partners and member institutions)
awards@msrdconsortium.org (For those who already have an active research award)

Hours:   Monday to Friday, 9:00 am to 5:00 pm EST
Phone: (202) 684-7953

 

MSHS Guideline for Deans Funding for COVID-19 Research

Send one page proposals, biosketch, and budget—as one PDF—to covidpilotgrants@mssm.edu.

General Notices

10/12/2021 to 02/16/2023 - Special Empahsis Notice (SEN): Health Services Research to Advance Health Equity

The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality’s (AHRQ) interest in receiving health services research grant applications that propose innovative and evidence-based interventions that advance the nation’s goal of achieving equity in the delivery of healthcare services including reducing disparities in quality of care, patient safety, healthcare utilization and access, and ultimately, health outcomes.

Deadline: 12-Oct-2021 , 16-Oct-2021 , 01-Nov-2021 , 07-Jan-2022 , 25-Jan-2022 , 01-Feb-2022 , 05-Feb-2022 , 12-Feb-2022 , 16-Feb-2022 , 01-May-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 01-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 01-Nov-2022 , 07-Jan-2023 , 25-Jan-2023 , 01-Feb-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023

More Information

NOT-AI-20-066 - Notice of Early Expiration of NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NOT-HD-20-017 - Notice of NICHD Participation in NOT-EB-20-012 "Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)"

Notice Number: NOT-HD-20-017

The purpose of this Notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is participating in NOT-EB-20-012 “Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)”.

More Information

NOT-MH-20-061 - Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-MH-20-061

The purpose of this Notice is to extend the data-harmonization effort at the National Institute of Mental Health (NIMH) announced in NOT-MH-15-009 to research protocols pertaining to the public health emergency caused by Coronavirus Disease 2019 (COVID-19), the disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

NIMH has already made a significant investment in a data repository to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in NOT-MH-15-009and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

More Information

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis

Notice Number: NOT-CA-20-054

The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

More Information

Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional")

Notice Number: NOT-NR-20-005

The purpose of this Notice is to inform applicants that the National Institute of Nursing Research (NINR) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
  • NSF encourages the research community to respond to this challenge through existing funding opportunities.
  • In addition, NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.
  • Complete guidance on submitting a RAPID proposal may be found in Chapter II.E.1 of the NSF Proposal and Award Policies and Procedures Guide.

More Information

Notice of Intent

Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative

Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative

Purpose: This Notice is to alert the community that NIH plans to publish Research Opportunity Announcements (ROAs) as part of the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) initiative. The solicited research will improve understanding of and develop strategies to prevent and treat post-acute manifestations of SARS-CoV-2 infection across the lifespan. The initial ROAs are expected to be published by mid-February 2021.

Projects will be funded utilizing NIH’s Other Transaction Authority (OTA), which offers flexibility and the ability to engage partners in collaborative innovation and problem solving. Initial awards are anticipated to be made in early March 2021. This Notice is being provided for informational purposes to allow potential applicants additional time to develop responsive applications. NIH reserves the right to modify the scope and objectives as described in this Notice. Final scope, objectives, and requirements will be set forth in the published ROAs.

Background: Some COVID-19 survivors report experiencing symptoms beyond the usual recovery time from the infection. In some cases, new symptoms and findings are reported that appear linked to the timing of acute infection but emerge subsequently and evolve over time.

Reported symptoms range from mild to incapacitating and can persist for months following acute disease. These symptoms and findings (i.e., post-acute sequelae) are reported in different organs and systems and can adversely affect overall quality of life.

The magnitude of the public health impact of these sequelae is currently unknown but potentially profound, given the numbers of individuals across the age spectrum who have been and will be infected with SARS-CoV-2, the virus that causes COVID-19. It is a public health priority to understand and develop strategies to prevent and treat PASC.

Research Initiative Details.The goal of the PASC Initiative is to systematically advance our understanding of the recovery process after SARS-CoV-2 infection and to prevent and treat PASC. Toward these ends, the overall PASC Initiative is designed to address three fundamental scientific questions: – What is the biologic basis of the heterogeneity in recovery from SARS-CoV-2 infection? – For those patients who do not fully recover or develop new symptoms/sequelae, what is the incidence/prevalence, clinical spectrum, and underlying biology? – What interventions might improve recovery after SARS-CoV-2 infection and prevent long-term disability due to PASC?In implementing the PASC initiative, NIH will solicit research proposals to understand recovery after SARS-CoV-2 infection and PASC. The PASC initiative will leverage a variety of platforms, including large and long-standing longitudinal studies; large-scale EHR/health systems-based cohort studies; COVID-19 clinical trials/networks; and COVID-19 registries, observational and clinical studies. These will be augmented by utilization of mobile and digital health strategies for patient recruitment, data collection, and follow-up. Applicants will be encouraged to leverage multidisciplinary teams to generate the critical data necessary to rapidly enhance understanding of PASC, including its epidemiology, risk factors for illness severity and outcomes, natural history, and pathophysiology. Exploratory clinical trials testing strategies to treat symptoms and prevent progression of SARS-CoV-2 infection to PASC are also an important part of this initiative and will be the subject of subsequent solicitations. Together, these activities will constitute a rigorous and comprehensive research program on PASC across the spectrum of COVID-19 clinical presentation, across diverse populations, and throughout the lifespan, leading to findings and innovative treatment and preventive strategies that are applicable to all who are affected, including populations that bear a disproportionate burden of SARS-CoV-2 infection.NIH intends for projects funded under this program to be part of a coordinated Consortium that will collectively pursue the goal of understanding, treating, and preventing PASC by collaboratively developing common protocol elements; adopting common data elements; and sharing data, biospecimens, and knowledge within the Consortium and with the broader research community.

Toward these ends, NIH plans initially to publish three ROAs to solicit applications for:

ROA #1: Clinical Research Studies targeting three domains: (a) Clinical Case-Based Recovery Meta-Cohort, (b) Autopsy Studies, and (c) EHR-/Health Systems-Based Analyses. Applications for this ROA may encompass one or more of these three domains.

a. Clinical Case-Based Recovery Meta-Cohort At the heart of the PASC Initiative is the SARS-CoV-2 Recovery Cohort, a collaborative meta-cohort that will leverage ongoing fit-for-purpose cohorts as well as new cohorts to facilitate the rapid launch of multi-disciplinary observational and mechanistic research on the incidence, risk factors, and mechanisms involved in PASC morbidity. This meta-cohort will bring together clinical cohorts of research participants across the lifespan with a history of SARS-CoV-2 infection, COVID-19, and/or PASC across the lifespan, of two main types:

i. Acute: Cohort studies with well-characterized pre-infection and/or acute infection baseline data and established plans for continued follow-up from the acute infection to understand the natural history and underlying biology of the heterogeneous recovery after SARS-CoV-2 infection.

ii. Post-acute: Cohort studies of the post-acute phase enrolling participants with SARS-CoV-2 infection, COVID-19, or PASC with appropriate comparison participants and conducting intensive investigation of relevant organ injury and other system dysfunction and continued longitudinal follow-up of health outcomes. The studies funded will constitute a meta-cohort encompassing inclusive participation reflective of appropriate diversity and enrolling adults and children. For the purposes of studies of adults, NIH anticipates assembling from across all the contributing cohorts a total of at least 20,000 cases of SARS-CoV-2 infection/COVID-19 cases and at least 1,000 PASC cases. For the purposes of studies of children, we anticipate assembling from across the contributing cohorts a total of at least 10,000 cases of SARS-CoV-2 infection/COVID-19 cases and at least 500 PASC cases. Preference may be given to applicants capable of studying large numbers of cases and appropriate comparison participants; this will be further detailed in the ROA. Applicants proposing smaller samples will be expected to provide strong justification for their approach based on other considerations, e.g., special population characteristics or deep pre-infection phenotyping, special investigations of specific organ dysfunction, etc.

b. Autopsy Studies: The goal of this effort is to provide in-depth histopathologic analysis of a broad range of organs and tissues in order to identify injury due to SARS-CoV-2 infection and/or its sequelae that lead to or contribute to PASC. Investigators will be expected to submit tissues to a biobank for distribution across the Consortium and more broadly with the research community.

c. EHR-/Health Systems-Based Studies: The goal of this effort isto advance the understanding and management of the post-acute effects of COVID-19 across the lifespan by: making innovative use of real world data such as electronic health records, health systems data, and other large data sets; by further expanding capabilities of existing data resources; leveraging health-systems based protocols to inform PASC clinical characterization through patient survey-based symptom reporting; and by working in an integrated fashion with other components of the coordinated NIH response to address PASC.

ROA #2: Clinical Science Core, for which applicants will be expected to:

•Foster collaboration across the Consortium; coordinate and provide logistical support(scheduling, meetings, communication platforms) for the PASC investigator consortium and all relevant working groups/committees, including platforms to solicit and incorporate patient viewpoints; facilitate use of toolkits of common data elements, surveys/questionnaires, and mobile health tools; incorporate use of various consent processes (e.g., e-consent) as applicable; interface with IRBs; and support the literature review in PASC.

•Provide expertise and statistical input on clinical study design, implementation, execution, and monitoring, including advising and coordinating the development and implementation of protocols/sub-study protocols; develop manual of procedures, case report forms, identification and selection of surveys and questionnaires, and recruitment strategies to promote inclusive participation; assure delivery of high-quality data, including mobile data, to the Data Resource Core; and develop monitoring procedures for study performance and safety.

Support and provide expertise in clinical research study data management, data quality control, study monitoring, statistical analyses, sample size calculations, data reports for oversight and monitoring boards and regulatory entities, analysis expertise and support for phenotyping in adults and children, including the acute and post-acute manifestations, at a clinical and biological level.

•Provide framework/infrastructure and statistical expertise for results analysis, interpretation and dissemination, and development of final phenotype characterization and diagnostic algorithms. •Coordinate receipt of the collection, analysis, deposition, and central management of patient biospecimens, transfer to the PASC biorepository (to be identified by NIH at a later date), and linkage of these biospecimens to clinical data in order to provide critical tools and resources for future PASC research.

ROA #3: Data Resource Core, for which applicants will be expected to:

•Facilitate the standardized collection of clinical data (i.e., usage of common data elements) and data harmonization, assist research projects with linking these data with other data, including but not limited to: publicly available sources (e.g., Census data, Area Deprivation Index, etc.), electronic health records (EHR) and others as needed, as well as perform quality control, data curation, and analyses, and provide data informatics tools.

•Maximize the value of the collective data sets and enable interoperability with other NIH COVID-19 research resources by supporting studies with a cloud-based data “workbench;” promoting adoption of common data elements and harmonized definitions of key variables; and facilitating seamless integration into existing large-scale well-curated genotypic and phenotypic data sets.

•Create a data coordination and analytics framework to compile and link data from extant clinical studies/networks, biosamples, imaging, EHR and related records data, mobile health data and other non-traditional data sources; and provide access to datasets for analysis by the research community.Additional ROAs may be issued in the future as needed.

Researchers planning to apply are strongly encouraged to read all three of these interrelated research opportunities when they are published.

Inquiries: Please direct all inquiries to: NHLBI_OTA@mail.nih.gov

NIH Administrative Supplements

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC’s web site to ensure they meet the IC’s requirements.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.

Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.

More Information

Notice of Changes to Funding Opportunities

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately in NOT-MD-21-008, Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities”.

More Information

NOT-HL-20-806 - NHLBI confirms participation in NOT-OD-20-119, NOT-OD-20-120, and NOT-OD-20-121 (Research on COVID-19 Testing among Underserved and/or Vulnerable Populations)

Notice Number: NOT-HL-20-806

More Information

NOT-OD-20-157 - Notice to Clarify and Correct Eligibility in Notices of Special Interest under the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) Program

Notice Number: NOT-OD-20-157

This notice makes corrections to clarify eligibility information in NOT-OD-20-119 “Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations” and NOT-OD-20-120 “Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations” and a deletion to correct responsiveness information for NOT-OD-20-119.

In both NOT-OD-20-119 and NOT-OD-20-120 where it

Currently states:

Eligibility

Eligible existing grants that can be revised in response to this NOSI are limited to eligible non-fellowship active research and resource grants and cooperative agreements. Currently funded grantees may apply for work that is related to their funded project, whether within the scope or outside of the scope of the current project, regardless of the time remaining on the current project. Grants currently in a no-cost extension are eligible to apply

is Updated to read:

Eligibility

Active research and resource grants, cooperative agreements, and small business grants (SBIR and STTRs) are eligible to apply. NRSA training and fellowship grants, and career development awards are not eligible to apply for funding. Currently funded recipients may apply regardless of the time remaining on the current project.Grants currently in a no-cost extension are eligible to apply.

For NOT-OD-20-119, an error is corrected by removal of a bulleted item, related to “Applications nonresponsive to this NOSI…”.

Where it is indicated:

Applications nonresponsive to terms of this NOSI will not be considered.The following types of projects would generally not be appropriate and may be deemed non-responsive:

Remove the bulleted line:

  • Projects that have limited testing capacity, that do not include FDA-authorized testing strategies or present a plan to incorporate approved testing strategies

More Information

NOT-OD-20-156 - Notice of Change to Funding Announcement (NOT-OD-20-048) by the Office of Research on Women's Health (ORWH), " Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)"

Notice Number: NOT-OD-20-156

The purpose of this notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) has made some changes, effective immediately, in NOT-OD-20-048, “Notice of Special Interest: Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)”.

The following text has been added to reflect changes in the NOSI (NOT-OD-20-048).

The Office of Research on Women’s Health (ORWH) announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 Trans-NIH Strategic Plan for Women’s Health Research “Advancing Science for the Health of Women.”

ORWH is encouraging application submissions and is seeking to support studies on the SARS-CoV-2 virus or COVID-19 disease in alignment with efforts across NIH to develop and implement effective therapeutics and vaccines and to accelerate research on technologies to validate and improve programs that will overcome barriers and increase uptake of effective therapeutics and vaccines at the point of care. Within the focus of this funding opportunity announcement, research topics of interest could include investigating the risk factors associated with COVID-19 disease prevalence among NIH-designated health disparity populations, women living in underserved rural or urban settings, pregnant and lactating women, women frontline healthcare workers, women with low socioeconomic status, and women experiencing homelessness or having justice system involvement.

Topics addressing intersectional and community-based research for older underserved women, residents of skilled nursing or long-term care facilities, and women providing care in the home to aging, disabled populations, or children (i.e., maternal caregiving) are areas of interest.

Research involving qualitative and quantitative techniques to assess social and behavioral processes that affect SARS-CoV-2 infection vulnerability and disease severity in underrepresented, understudied, and underreported (U3) populations are also areas of interest.

Proposals are encouraged to incorporate a variety of media, such as graphic medicine or other arts-based approaches to engage with underrepresented, understudied, and underreported (U3) populations to achieve the goals of the applications.

More Information

NOT-OD-20-149 - Notice of Correction to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" for Award Information about Clinical Trials

Notice Number: NOT-OD-20-149

This notice corrects RFA-OD-20-013 “Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)” in Section II. to indicate that this funding opportunity accepts applications that either propose or do not propose clinical trial(s).

This funding opportunity announcement is corrected for Section II. Award Information – Clinical Trial?, as follows:

Currently reads:

Not Allowed: Only accepting applications that do not propose clinical trial

Is modified to read:

Optional: Accepting applications that either propose or do not propose clinical trial(s)

More Information

NOT-HL-20-801- National Heart, Lung, and Blood Institute -Notice of NHLBI Participation in NOT-OD-20-097 "NOSI regarding Availability of Admin Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-HL-20-801

The purpose of this Notice is to inform potential applicants that NHLBI’s participation in NOT-MH-20-053 “Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19” will cease on July 31, 2020. An application submitted in response to NOT-MH-20-053 that is intended for NHLBI and received on August 01, 2020 or later will be withdrawn.

More Information

NOT-HL-20-799 - National Heart, Lung, and Blood Institute- Notice of NHLBI Participation in NOT-OD-20-097 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences"

Notice Number: NOT-HL-20-799

The purpose of this Notice is to inform potential applicants that NHLBI’s participation in NOT-OD-20-097 “Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences” will cease on July 31, 2020. An application submitted in response to NOT-OD-20-097 that is intended for NHLBI and received on August 01, 2020 or later will be withdrawn.

More Information

NOT-AG-20-036 - Notice of NIA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-AG-20-036

This Notice informs potential applicants that the National Institute on Aging (NIA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-DA-20-061 - Notice of NIDA Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DA-20-061

The purpose of this Notice is to inform potential applicants that the National institute of Drug Abuse (NIDA) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DC-20-010 - Notice of NIDCD's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-010

The purpose of this Notice to inform potential applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional).”

More Information

NOT-OD-20-111 - Notice of ORWH Participation in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”

Notice Number: NOT-OD-20-111

The purpose of this Notice is to inform potential applicants that the Office of Research on Women’s Health (ORWH) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-MH-20-064 - Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-MH-20-064

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH) will participate, effective immediately, in PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-DK-20-026 - Notice of Additional Activity Code Accepted for "NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK"

Notice Number: NOT-DK-20-026

The purpose of this Notice is to add the U24 activity code to the activity codes eligible for submissions and adjust the language for parent awards to be eligible under NOT-DK-20-018: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK.

More Information

NOT-AA-20-007 - Notice of Participation of NIAAA in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional"

Notice Number: NOT-AA-20-007

The purpose of this Notice is to inform applicants that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

More Information

NOT-CA-20-048 - Notice of National Cancer Institute (NCI) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-CA-20-048

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PA-18-935, “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-DC-20-003 - Notice of NIDCD's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-DC-20-003

The purpose of this Notice is to inform applicants that the National Institute on Deafness and Other Communication Disorders (NIDCD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”. The following changes and updates are made to PA-18-935 (shown in italics) to reflect NIDCD’s participation in this funding opportunity announcement (FOA).

More Information

NOT-HG-20-034 - Notice of NHGRIs Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-HG-20-034

The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

NOT-MD-20-018 - Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

Notice Number: NOT-MD-20-018

The purpose of this Notice to inform potential applicants that the National Institute on Minority Health and Health Disparities (NIMHD) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional).”

More Information

NOT-TR-20-015 - Notice of NCATS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

Notice Number: NOT-TR-20-015

The purpose of this Notice is to inform applicants that the National Center for Advancing Translational Sciences (NCATS) will participate, effective immediately, in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”.

More Information

NIH NOSI (Notice of Special Interest)

NOT-OD-20-097 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Notice Number: NOT-OD-20-097

This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

More Information

NOT-TR-21-006 - National Center for Advancing Translational Sciences/NIH/DHHS - Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Notice Number: NOT-TR-21-006

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

More Information

NOT-AT-20-011 - Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AT-20-011

NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-EB-20-003 - Notice of NIBIB's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"

Notice Number: NOT-EB-20-003

The purpose of this Notice is to inform applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate, effective immediately, in PA-20-135 “Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)”.

When applying please follow the additional instructions in the corresponding NOSI and include the NOSI # as indicated.

More Information

NOT-MD-21-020 - Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional)

Notice Number: NOT-MD-21-020

NIMHD is soliciting supplements to active NIMHD grants and cooperative agreements to support research on HIV/AIDS in NIH-designated populations that experience health disparities, including Blacks or African Americans, Hispanics or Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities. The purpose of this NOSI is to emphasize the continued importance of conducting research on HIV/AIDS that will further the EHE effort, including but not limited to research on how the COVID-19 pandemic and structural racism and discrimination affect HIV risk, prevention, and treatment among populations that experience health disparities.

Release Date: July 6, 2020

More Information

NOT-AI-20-058 - Notice of Early Expiration of "Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)”

Notice Number: NOT-AI-20-058

The purpose of this Notice is to inform the extramural community that NOT-AI-20-034, “Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)” is rescinded effective immediately. NOT-AI-20-034 is replaced by NOT-AI-20-059 which highlights very specific needs for competitive revision applications to NIAID grants to facilitate the Federal SARS-CoV-2/COVID-19 research response.

Release Date: July 6, 2020

More Information

10/15/2021 to 09/07/2023 - NOT-MH-21-230 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings

The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on detection and intervention to prevent or treat mental health concerns, symptoms or disorders including drug-related conditions among unemployed and underemployed people participating in employment programs and job training settings (referred to here as “employment service customers” or “customers”). Considering the COVID-19 pandemic, the sharp rise and potentially long duration of unemployment raises concerns about the development and worsening of mental health symptoms and disorders, drug use behaviors, and suicide risk and necessitates further research to confirm the efficacy or demonstrate effectiveness of strategies in this area.

Deadlines: 15-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023

More Information

10/15/2021 to 06/05/2024 - NOT-OD-21-100 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.

Deadlines
15-Oct-2021 , 16-Oct-2021 , 14-Dec-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024

More Information

10/16/2021 to 09/07/2024 - NOT-AA-21-028 - Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes

This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.

Application Deadlines: 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

10/16/2021 to 05/07/2024 - NOT-HD-21-026 - Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth

Pre-existing disparities and apparent challenges in resources for treatment and care of children experiencing abuse call for more data and research resources to identify, substantiate and improve care and ultimately outcomes for vulnerable children and youth during and following the current crisis. It is anticipated that research stemming from this NOSI will help to provide greater recognition of the need for better resources and support for vulnerable children. More touchpoints for communication, identification and screening for risks of child trauma, and injury will help inform processes for screening, identification, treatment and care in new and emerging disaster related contexts in the future.

Application Deadlines: 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024

More Information

10/16/2021 to 09/07/2024 - NOT-DA-20-084 - National Institute on Drug Abuse/NIH/DHHS - Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.

Deadlines: 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

10/16/2021 to 09/07/2024 - NOT-DA-21-011 - Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

Notice Number: NOT-HD-20-021

The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.

Application Deadlines: 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

10/16/2021 to 09/07/2024 - NOT-DA-21-001 - National Institute on Drug Abuse/NIH/DHHS - Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain

National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.

Deadlines: 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024

More Information

10/16/2021 to 06/16/2023 - NOT-HD-20-021 - National Institute of Child Health and Human Development/NIH/DHHS - Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract

Notice Number: NOT-HD-20-021

Submission Dates: 16-Oct-2021 , 05-Feb-2022 , 16-Feb-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Feb-2023 , 16-Feb-2023 , 05-Jun-2023 , 16-Jun-2023

The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.

More Information

10/16/2021 to 10/16/2023 - NOT-OD-21-092 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed)

This Notice invites applications specifically aimed at developing or building upon existing technological tools to improve diagnosis, assessments, interventions, management, and outcomes for infants, children, adolescents and adults with Down Syndrome.

Application Deadlines: 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023

More Information

10/16/2021 to 09/07/2024 - NOT-HD-21-038 - National Institute of Child Health and Human Development/NIH/DHHS - Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities

This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.

Application Deadlines: 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024

More Information

2022 NIH NOSI (Notice of Special Interest)

01/07/2022 to 09/07/2022 - NOT-MH-21-225 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children

NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 – 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios.

Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022

More Information

01/07/2022 to 06/05/2024 - National Institutes of Health/DHHS - Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).

Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024

More Information

07/11/2022 to 07/0/2023 - NOT-FD-21-014 - Notice of Special Interest (NOSI): Add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN)

Notice Number: NOT-FD-21-014

The purpose of this notice is to inform potential applicants to the Veterinary Laboratory Investigation and Response Network (Vet-LIRN), about a special interest in applications focusing on COVID-19 animal diagnostics.

Deadlines: 11-Jul-2022 , 10-Jul-2023

More Information

09/08/2022 - NOT-DC-20-008 - Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Notice Number: NOT-DC-20-008

Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

Expiration Date: Sept 8, 2022

More Information

2023 NIH NOSI (Notice of Special Interest)

01/08/2023 - NOT-AI-21-008 - Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)

Notice Number: NOT-AI-21-008

NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious diseases, including fundamental immunology research that aims to understand the complex interactions between pathogens and their human hosts and generate the knowledge essential for developing safe and effective treatments and vaccines. The mechanisms by which complement influences immune responses have been under appreciated, and a better understanding of complement action will inform high priority adjuvant and vaccine development, and also shed light on the pathogenesis of infections such as SARS CoV-2.

Release Date: February 4, 2021
First Available Due Date: June 5, 2021
Expiration Date: January 8, 2023

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

03/15/2023 - NOT-HS-21-010 - Agency for Healthcare Research and Quality/DHHS - Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic

Notice Number: NOT-HS-21-010

The purpose of this Special Emphasis Notice (SEN) is to inform the research community that the Agency for Healthcare Research and Quality is interested in receiving health services research grant applications to advance our nation’s understanding of the substance use disorder crisis and provide solutions for addressing it.

More Information

04/02/2023 - NOT-MH-20-040 - NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional)

Notice Number: NOT-MH-20-040

The purpose of the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training is to support advanced research opportunities for exceptional individuals holding the MD/PhD degree who are early in their research careers and thereby help these individuals transition efficiently and effectively from the period of clinical training to the next stage of their research careers. This administrative supplement program will provide focused, protected research time for eligible individuals during residency and/or clinical fellowship. The proposed research experience must have the potential to contribute significantly to the candidate’s research career.

Release Date: April 14, 2020
First Available Due Date: April 01, 2021
Expiration Date: April 02, 2023

You must apply to the appropriate Funding Opportunity Announcement and include the NOSI #. Please read the NOSI for complete information.

More Information

05/08/2023 - Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AG-21-015

Release Date: January 26, 2021
First Available Due Date: March 04, 2021
Expiration Date: May 08, 2023

NIA is issuing this Notice of Special Interest (NOSI) to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. Beyond effects on individuals, this pandemic has brought about unprecedented social and economic disruption that is expected to have long-term and profound effects on the health of the population. These effects will likely be particularly acute for NIH-designated health disparity populations, and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.

More Information

05/08/2023 - Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-DE-21-001

Release Date: January 26, 2021
First Available Due Date: June 05, 2021
Expiration Date: May 08, 2023

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19).

More Information

2024 NIH NOSI (Notice of Special Interest)

01/28/2024 - NOT-DA-20-058 - Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders

Notice Number: NOT-DA-20-058

There is an urgent need for remotely delivered Substance Use Disorder (SUD) treatments to reduce patient burden and for methods to conduct clinical trials remotely. The purpose of this NOSI is to stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for SUD, and to develop tools for remote collection of data in clinical trials of treatments for SUD.

Release Date: June 29, 2020
First Available Due Date: October 05, 2020
Expiration Date: January 08, 2024

More Information

09/08/2024 - NOT-DA-21-017 - Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19

Notice Number: NOT-DA-21-017

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.

Release Date: February 4, 2021
First Available Due Date: May 5, 2021
Expiration Date: September 08, 2024

More Information

09/08/2024 - NOT-DA-21-018 - Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders

Notice Number: NOT-DA-21-018

NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.

Release Date: February 3, 2021
First Available Due Date: May 7, 2021
Expiration Date: September 8, 2024

More Information

Continuous Submission

American College of Chest Physicians - CHEST Foundation COVID-19 Community-based Grant

As the charitable foundation for the American College of Chest Physicians, the CHEST Foundation has a mission of championing lung health by supporting clinical research, patient education, and community service. During this time of need, the CHEST Foundation is focusing efforts on assisting those making a difference in their communities during the COVID-19 pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Brookhaven National Laboratory - COVID-19 Research Support

The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Central European Research Infrastructure Consortium (CERIC) - COVID-19 Fast Track Access

In order to facilitate the research on the COVID-19, CERIC has set up a dedicated Fast Track Access to a selected number of instruments. The dedicated Fast Track Access will allow to access the selected instruments for research related to the COVID-19, without the necessity to undergo the regular evaluation procedure and be scheduled within one month from the submission of the proposal, based on the feasibility evaluation performed by the facility.

More Information

Coalition for Epidemic Preparedness Innovations (CEPI) - CEPI partner NIBSC - Partners for Sourcing Serum or Plasma from Individuals Recovered from Infection with SARS-CoV-2 Variants for the Development of Antibody Working Standards and Reference Panels

Through a joint effort in 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Biological Standards and Control (NIBSC), and the World Health Organization (WHO) provided COVID-19 vaccine developers and the entire scientific community with a research reagent for an anti-SARS-CoV-2 antibody, an International Reference Panel and the first WHO International Antibody Standard for assay calibration. These materials are constituted of plasma samples sourced from SARS-CoV-2 convalescent patients.

More Information

COVID-19 Fast Track Access

To facilitate research on COVID-19, CERIC has set up a dedicated Fast Track Access to a selected number of instruments including 600 and 800 MHz NMR, SAXS light scattering laboratory, Cryo EM, synchotron beamlines for Small Angle X-ray scattering and X-ray diffraction, and Synchroton Infrared Source for Spectroscopy and Imagine. Due to the travel restrictions in place for several countries, remote access will be preferred.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

COVID-19 Relief Fund

Robin Hood anticipates making grants to 501(c)(3) organizations in New York City that are well-positioned to serve low-income communities. The initial grants, expected to last three months in duration, will average $45,000.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Diamond Light Source - Rapid Access Call for Proposals: SARS-CoV-2

As part of Diamond’s effort to combat COVID-19 (as demonstrated by the fragment screening campaign against SAR-CoV-2 Main protease), fragment screening expertise and infrastructure are offered to users working on Covid-19 related projects.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Empire State Development - Biodefense Commercialization Fund

The New York State Urban Development Corporation d/b/a Empire State Development (hereinafter “ESD”) hereby establishes the $40 million Biodefense Commercialization Fund (“the Fund”) as a component of the Life Sciences Initiative Program. The Fund is intended to encourage and accelerate the development and commercialization of solutions for serious infectious disease threats, including COVID-19 and its variants, while fostering the creation of new life science businesses and supporting industry growth. The Fund will offer grants to startups and academic centers that are developing promising diagnostics, vaccines, therapeutics, and such other innovations as epidemiological surveillance tools, environmental controls, and clinical care advances that address or mitigate infectious disease threats.

Continuous Submission

More Information

European Synchrotron Radiation Facility - Covid-19 Scientific Research

The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Euro-Bioimaging - Fast Track Access to Biological and Biomedical Imaging Technologies for COVID-19 Research Projects

This opportunity offers access to biomedical imaging technologies to to scientists who have COVID-19 related research projects that need imaging resources.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Mail-in Protein-to-Structure Services to Support Structural Biology Research Related to COVID-19 at the EMBL Grenoble HTX Lab and the Joint ESRF-EMBL MX Beamlines

The ESRF-EMBL Joint Structural Biology Group (JSBG) invite COVID-19 related proposals that can benefit from the seamless integration of the EMBL High throughput Crystallization Facility (HTX Lab) with the highly automated JSBG MX beamlines at the ESRF. The pipeline starts with mail-in samples and integrates crystallization screening, crystal optimization, ligand soaking if required and eventually fragment screening with libraries of up to 1200 fragments. Crystals obtained will be automatically harvested and passed to the ESRF for automated X-ray data collection, with real-time access to experimental results and parameters. This pipeline is uniquely suited to support of structural biology projects in conditions of confinement and restricted access to labs. The HTX lab is already accepting crystallization projects on COVID-19 related research and three ESRF beamlines (MASSIF-1 (ID30A-1), ID30B and ID23-2) will become operational after 11 May 2020.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

European Synchrotron Radiation Facility - Covid-19 Scientific Research

The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.

Continuous Submission

More Information

Extreme Science and Engineering Discovery Environment (XSEDE) - COVID-19 HPC Consortium

The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. XSEDE hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Federal Communications Commission - COVID-19 Telehealth Program

The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.

Continuous Submission

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Ginkgo Bioworks - Access to Platform for Partner COVID-19 Projects

Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Global Innovation Fund Grant Program

The Global Innovation Fund was set up to confront global development challenges by funding innovations with the potential to improve the lives of the world’s poorest people. GIF will devote resources to new deals for COVID-19-related grantmaking in 2020.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

ICESCO prize for Fighting against Coronavirus

In response to the World Health Organization’s appeal to the international community to “seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact”, the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Jacob and Valeria Langeloth Foundation - COVID-19 Rapid Response Fund

The Jacob and Valeria Langeloth Foundation created the COVID-19 Rapid Response Fund (CRRF) to enable Langeloth to address organizations’ urgent and critical needs that have arisen due to the COVID-19 global pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Johnson (Robert Wood) Foundation - Pioneering Ideas: Exploring the Future to Build a Culture of Health

The Pioneer team seeks to anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in the United States can live their healthiest life possible. The Pioneering Ideas: Exploring the Future to Build a Culture of Health call for proposals (CFP) seeks applications from visionary thinkers across the nation who are doing cutting-edge work to advance health equity.

More Information

National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS - Rapid Acceleration of Diagnostics (RADx): Fast-Track Program for COVID-19 Test Development and Distribution

National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022, 16-Feb-2022, 07-May-2022, 16-Jun-2022, 07-Sep-2022, 16-Oct-2022, 07-Jan-2023
This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data.

A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Novartis Foundation - COVID-19 Community Response Fund

In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Road Alliance - Response to COVID-19

Open Road is offering charitable grants and loans to nonprofits and social enterprises impacted by COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Open Call for Innovation Focus Area: COVID-19: Rapid Sanitising Technology

In addition to its regular Open Call, DASA publishes Open Call innovation focus areas to increase awareness of some of the enduring challenges faced by defence and security stakeholders, and to stimulate the submission of relevant innovative proposals.

For the current focus area: COVID-19: Rapid Sanitising Technology, DASA is looking to identify, develop and demonstrate rapid sanitising technologies for ambulances that have transported a patient with suspected COVID-19.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pollination Project - COVID-19 Rapid Response Grants

As of March of 2020, The Pollination Project has redirected all of our focus, support, and seed funding to uplifting the selfless actions of frontline grassroots volunteers working in response to COVID-19 (aka coronavirus) in their communities. Now until it is no longer needed, The Pollination Project will accept applications for volunteer community projects that address: direct needs around water, sanitation, and hygiene; community & emotional resilience; and virtualization of existing grassroots projects.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Pioneering Ideas: Exploring the Future to Build a Culture of Health

The Robert Wood Johnson Foundation (RWJF) has issued a call for proposals, “Pioneering Ideas: Exploring the Future to Build a Culture of Health”, seeking proposals that are primed to influence health equity in the future. They are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, they welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Priority Access Call for Work on Combating COVID-19

The Paul Scherrer Institute (PSI) has opened a “PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Seventh Generation Fund - Flicker Fund

The Flicker Fund was created as a way to rapidly respond to stressed Indigenous communities on the frontlines of COVID-19. The Fund launched within days of learning about the pervasiveness of the virus and its impact on Indigenous communities.

More Information

Scherrer (Paul) Institute - Priority Access Call for Work on Combating COVID-19

The Paul Scherrer Institute (PSI) has opened a “PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.

More Information

Social Science Research Council - Just Tech Covid-19 Rapid-Response Grants

The Social Science Research Council (SSRC), as part of its Just Tech program, seeks proposals from across the social sciences and related fields that address the risks, opportunities, and challenges posed by public health surveillance stemming from the Covid-19 pandemic. The sponsor specifically encourages proposals that interrogate the role the public and private sectors may play in mitigating or exacerbating the health crisis, the effects of which are already unevenly distributed.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

Turkish Philanthropy Funds - TPF COVID-19 Community Relief Fund

The sponsor has created the COVID-19 Community Relief Fund to support containment, response and recovery activities for those affected and for the responders.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

October 2022 Application Deadlines

10-03-2022 - RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)

01-May-2020, 01-Jun-2020, 01-Jul-2020, 03-Aug-2020, 01-Sep-2020, 01-Oct-2020, 02-Nov-2020, 01-Dec-2020, 04-Jan-2021, 01-Feb-2021, 01-Mar-2021, 01-Apr-2021, 03-May-2021, 01-Jun-2021, 01-Jul-2021, 02-Aug-2021, 01-Sep-2021, 01-Oct-2021, 01-Nov-2021, 01-Dec-2021, 03-Jan-2022, 01-Feb-2022, 01-Mar-2022, 01-Apr-2022, 02-May-2022, 01-Jun-2022, 01-Jul-2022, 01-Aug-2022, 01-Sep-2022, 03-Oct-2022
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

More Information

In addition, please review the SPIN Getting Started Instructions for information about beginning your individual search.

February 2023 Application Deadlines

02/03/2023 - BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement

Please see Special Instructions 001 Issuance for Easy Broad AgencyAnnouncement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of itsEZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV. See attachment(s).This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest(AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) inthe Office of Biomedical Advanced Research and Development Authority(BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal AcquisitionRegulation (FAR). Abstract submissions selected for award are consideredto be the result of full and open competition and in full compliance with41 U.S.C.

Application Deadline February 3, 2023

More Information

March 2023 Application Deadlines

03/17/2023 - PAR-20-310 - National Institutes of Health/DHHS - Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

Application Deadlines: 17-Mar-2022 , 17-Nov-2022 , 17-Feb-2023 , 17-Mar-2023

More Information

September 2023 Application Deadlines

09/07/2023 - PA-20-172 - National Institutes of Health/DHHS - Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

Application Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023

More Information

December 2023 Application Deadlines

12/11/2023 - National Institutes of Health/DHHS - Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, piloting innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system-related function and disorders throughout life, relevant to LMICs. Research on the full spectrum of neuro-health, neurological, neuromuscular, sensory, neuropsychiatric, cognitive, behavioral and neurodevelopmental function and disorders may span the full range of science from basic to clinical to translation and implementation research. Scientists in LMIC institutions may partner with scientists in other LMIC institutions and/or U.S. institutions . Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups). These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable neuro-health research capacity in LMICs to address brain, nervous system and neuromuscular related development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.

Application Deadlines: 15-Nov-2022 , 09-Dec-2022 , 15-Nov-2023 , 11-Dec-2023

More Information

January 2024 Application Deadlines

01/07/2024 - National Heart, Lung, and Blood Institute/NIH/DHHS - Notice of Special Interest (NOSI): Resilience and Vulnerability following Acute Heart, Lung, Blood, and Sleep Insults in People with HIV (R01, Clinical Trial Not Allowed)

This NOSI encourages the submission of research project applications focused on understanding the long-term manifestations of acute HLBS illnesses with an emphasis on host response, viral pathways, and mechanisms that contribute to long-term manifestations in the context of HIV. Proposals considered responsive to the NOSI may address questions across the spectrum of basic science to population science.

Application Deadlines: 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024

More Information

May 2024 Application Deadlines

05/07/2024 - National Institute of Child Health and Human Development/NIH/DHHS - Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups – neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and
post-natal period.

Application Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024

More Information

05/25/2024 - EDC Form Design Principles - Making Health Care Safer in Ambulatory Care Settings and Long-term Care Facilities (R18)

The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health
care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S.
Department of Health and Human Services and with other partners to make sure that the evidence is
understood and used. AHRQ’s Center for Quality Improvement and Patient Safety (CQuIPS) works to
ensure patient safety in multiple settings with recent efforts to increase the development of processes
including measures, metrics, tools and practices to increase patient safety in the ambulatory care setting
and in long-term care facilities. This Funding Opportunity Announcement (FOA) will fund large research
demonstration and implementation projects that pertain to ambulatory care settings and long-term care
facilities with a focus on implementing evidence-based processes to improve patient safety, especially
those involving transitions in care. AHRQ is interested in studies in these two settings that develop,
utilize, and evaluate strategies to implement existing measures, metrics, tools or practices that have
already been validated and have been shown to be efficacious in improving patient safety sites.

Application Deadlines: 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023 , 25-Jan-2024 , 25-May-2024

More Information

June 2024 Application Deadlines

06/21/2024 - National Institutes of Health/DHHS - Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)

This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. Researchers proposing Basic Experimental Studies with Humans (BESH) should consider the companion FOA, PAR-21-349, “Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)”.

Application Deadlines: 21-Jun-2022 , 21-Jun-2023 , 21-Jun-2024

More Information

September 2024 Application Deadlines

09/07/2024 - National Institutes of Health/DHHS - The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.

Application Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024

More Information

09/07/2024 - National Institutes of Health/DHHS - Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.

Application Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024

More Information

09/08/2024 - National Institute on Drug Abuse/NIH/DHHS - Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research examining how the COVID-19 pandemic has impacted drug markets and overdose risk. It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).

Application Deadlines: 11-Jan-2022 , 03-May-2022 , 08-Sep-2022 , 11-Jan-2023 , 03-May-2023 , 08-Sep-2023 , 11-Jan-2024 , 03-May-2024 , 08-Sep-2024

More Information

October 2024 Application Deadlines

10/05/2024 - Food and Drug Administration/DHHS - RFA-AT-22-001 -- NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional)

This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve health and care delivery, with a particular focus on health care systems (HCS) with less historical involvement in research studies focused on improving health outcomes for US patient populations. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a trial conduct phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the “real world” assessment of health care strategies and clinical practices and procedures in health care systems (HCS) that lead to improved care for populations in a variety of healthcare contexts, with a strong focus on populations with health disparities. Results from the pragmatic studies supported by this FOA should inform policy makers, payers, doctors and patients across diverse patient care settings. This FOA requires that the intervention under study be embedded into health care delivery system, “real world” settings. Studies can propose to integrate multi-modal or multiple interventions that have demonstrated efficacy into HCS; or implement HCS changes to improve adherence to evidence-based guidelines. Trials should be conducted across three or more health care systems (HCS) that provide care to patient populations and will become part of and work with the NIH HCS Research Collaboratory. The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. Awarded applicants will work with the HCS CCC (https://rethinkingclinicaltrials.org/) to facilitate further planning and refinement of the proposed study.

Application Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024

More Information

10/05/2024 - Food and Drug Administration/DHHS - RFA-FD-22-003 -- Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Optional

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance COVID-19 health equity research. Areas of interest include: Proposals that focus on advancing racial and ethnic minority participation in COVID-19/COVID-19 variant clinical trials and/or contribute to informing the continued evaluation of the safety and efficacy of FDA approved products (therapeutics, diagnostics, and vaccines) or products subject to EUAs/EUA expansion for the treatment, prevention, or diagnosis of COVID-19. Proposals that support the evaluation of outcomes by demographic data including, but not limited to, ethnicity, race, age, disability, and geography. Proposals that support COVID-19 research to understand diverse patient perspectives, preferences, and unmet needs

Application Deadlines: 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024

More Information

December 2024 Application Deadlines

12/06/2022 to 12/10/2024 - National Institute for Occupational Safety & Health/CDC/DHHS - Cooperative Research Agreements Related to the World Trade Center Health Program (U01)

The purpose of this announcement is to help address the Zadroga Act research mandate (Public Law 111–347), and in consultation with the World Trade Center (WTC) Scientific/Technical Advisory Committee, NIOSH is soliciting applications for scientifically rigorous research (Title 42 USC §300mm–51) to help answer critical questions about: Physical and mental health conditions that may be related to the September 11, 2001, terrorist attacks; Diagnosing WTC-related health conditions for which there has been diagnostic uncertainty; and Treating WTC-related health conditions for which there has been treatment uncertainty.

Application Deadline: 06-Dec-2022 , 05-Dec-2023 , 10-Dec-2024

More Information

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.

Research 411 Portal

Still Need Help?